Boehringer Ingelheim, Kyowa Kirin enter into license agreement to develop fibro-inflammatory diseases treatment
Ingelheim: Boehringer Ingelheim and Kyowa Kirin Co., Ltd. have announced that they have entered into a license agreement to develop a novel, first-in-class treatment for fibro-inflammatory diseases.
Under the terms of the agreement, Boehringer Ingelheim will receive exclusive, worldwide rights from Kyowa Kirin to develop novel, first-in-class treatments for fibro-inflammatory diseases. Kyowa Kirin is eligible to receive up to EUR 410 million comprising of an upfront payment, success-based development, regulatory, and commercial milestone payments, in addition to royalties on sales.
Fibro-inflammatory diseases result from chronic inflammation caused by a variety of factors including persistent infections, autoimmune reactions, allergic responses and tissue injury. Examples are systemic sclerosis, inflammatory bowel disease, lung fibrosis and others. They are a leading cause of morbidity and mortality. Living with fibro-inflammatory diseases greatly impact patients’ lives, both physically and emotionally and they account for more than one third of deaths worldwide.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.